SynthesisLasers in medical science2026
Light-emitting diode therapy for the prevention and treatment of radiodermatitis in women with breast cancer: systematic review.
Synthesis in Lasers in medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer, the most common cancer worldwide, is treated with surgery, chemotherapy, and radiotherapy. Radiotherapy reduces recurrence and mortality but causes radiodermatitis in over 90% of patients. Current preventive and topical treatments have limited efficacy. Photobiomodulation therapy shows promise for preventing and treating radiodermatitis, but the evidence is limited and controversial. This article aims to systematically review the efficacy of LED therapy in preventing and treating radiodermatitis in women with breast cancer undergoing radiotherapy. This systematic review adheres to PRISMA guidelines, registered in PROSPERO (CRD42023467705), and searches databases (PubMed, Scopus, Cochrane, etc.) for randomized controlled trials (RCTs) and non-randomized trials from 2000 to July 2025. The inclusion criteria targeted human trials of LED therapy for radiodermatitis in breast cancer patients. Study quality was assessed using RoB 2 and ROBINS-I tools. From 882 articles, six studies (three RCTs, three non-randomized; 233 participants) were included. Four studies demonstrated that LED therapy reduced radiodermatitis severity (e.g., 94.7% Grade 0–1 in the LED group vs. 14.3% in the control group; p < 0.0001) and treatment interruptions. Three studies reported faster healing and pain reduction in acute radiodermatitis, but chronic radiodermatitis showed no improvement. One study found no significant benefit (p > 0.05). Study quality varied, with two RCTs rated low risk and one high risk. LED therapy shows promise for managing acute radiodermatitis but requires large-scale RCTs with standardized protocols to confirm efficacy, optimize parameters, assess chronic radiodermatitis, and evaluate cost-effectiveness for integration into clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.